Scientists Yet To Discover Biomarkers To Predict Cardiovascular Risks

Researchers have revealed that measuring the known biomarkers modestly improves the prediction of future heart attack, but not enough to change preventive therapies.

Although conventional risk factors, like as smoking, hypertension, cholesterol levels and age, can identify individuals at the highest risk for heart attack or stroke, many people without these factors still experience these potentially devastating events.

Combination of Biomarkers Promises Early Diagnosis And Improved Treatment For Heart Failure.
Scientists have identified that a combination of two more efficient applications of biomarkers of heart failure can promise an earlier diagnosis and improved treatment for patients.

"While there currently does not appear to be a role for routine use of biomarkers in screening for cardiovascular risk, our data do not exclude a role for biomarkers in selected patients," said Dr. Thomas Wang, of the MGH Heart Center, the study's senior and co-corresponding author.

"We're still optimistic that new technologies will lead to the discovery of biomarkers that could help us move toward offering truly personalized cardiovascular risk prediction," he added.

The current study was focused on two biomarkers that have been extensively studied in cardiovascular disease, C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (N-BNP), and four that recently have been identified as relating to cardiovascular risk, Cystatin C, Lp-PLA2, MR-proADM and MR-proANP.

Study Pinpoints Novel Cancer Gene and Biomarker
Dana-Farber Cancer Institute scientists' discovery of a cancer-causing gene – the first in its family to be linked to cancer – demonstrates how the panoramic view of genomics.

The researchers found that two of the studied biomarkers, N-BNP and MR-proADM, did significantly improve the prediction of coronary events, defined as a heart attack or death from ischemic heart disease.

N-BNP and C-reactive protein improved the prediction of cardiovascular events, which are coronary events plus strokes.

But when the ability of biomarkers to move individual patients into higher- or lower-risk categories was analyzed, the potential impact on treatment decisions was minimal.

"Since choice of therapies may depend on the risk category a patient falls into, moving patients between risk categories could lead to a change in therapy," said co-author Dr. Christopher Newton-Cheh, of MGH Heart Center.

"While there was more category movement among participants initially classified as intermediate-risk, that resulted primarily from movement to lower risk levels, so we still need to find biomarkers that can make a clinically significant difference in predicting cardiovascular risk" he added.

The study appears in the Journal of the American Medical Association.

Source-ANI
ARU